IRF4 is involved in the differentiation and maturation of B-cells, plasma cells, as well as memory T-cells, and hence, most clinical trials targeting this molecule are associated with lymphomas or plasma cell neoplasms. This evidence concerns the gene IRF4 and lymphoma.